Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 8/20 | 0.33 |
| ▸ | HTR6 | P50406 | 8/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 6/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623980 | 0.85 | KCNH2 (0.38) | KCNH2SSTR3HTR7HTR6HTR1A | |
| SCHEMBL10233671 | 0.79 | — | — | |
| SCHEMBL22623903 | 0.77 | ACACB (0.37) | IDO1CYP11B1CYP11B2 | |
| SCHEMBL25404428 | 0.75 | — | — | |
| SCHEMBL859620 | 0.75 | — | — | |
| SCHEMBL17493899 | 0.75 | — | — | |
| SCHEMBL858930 | 0.75 | — | — | |
| SCHEMBL10190927 | 0.75 | CHRM5 (0.39) | IDO1HTR2A | |
| Hydrochloric Acid SCHEMBL25404165 | 0.73 | KCNH2 (0.41) | KCNH2SSTR3HTR7HTR6HTR1A | |
| SCHEMBL18382132 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | KCNH2 1935/4885SSTR3 4494/4885HTR7 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.